Scientific Presentations and Publications

Multicenter, Open-label, Post-Authorization Safety Study (PASS) of Elsulfavirine (Elpida®) Used In First-line Therapy For HIV-1- Infected Patients Added to Standard ART (NNRTI + two NRTIs) (GLASGOW 2020)

Safety and PK Study of VM-1500A-LAI, a Novel Long-Acting Injectable Therapy for HIV (CROI 2020)

Drug resistance to novel non-nucleoside reverse transcriptase inhibitor Elsulfavirine among treatment-naïve, HIV-infected Caucasian and Asian patients (AIDS 2020)

Development of Elsulfavirine/VM1500A Long Acting Injectable and Once Weekly Oral Formulations for Treatment and Prevention of HIV-1 Infections (Military Health System Research Symposium)

Pharmacokinetics of VM1500A Long Acting Injectable Formulations for HIV-1 Infections Treatment and Prevention after Repeat-Dose Administration in Dogs (AIDS 2018)

Elsulfavirine-based Antiretroviral Treatment in Combination with Two NRTIs: 96 Weeks (AIDS 2018)

Pre-clinical Development of Elsulfavirine/VM1500A Long Acting Injectable Formulations (EACS 2017)

Pre-clinical Pharmacokinetics of Elsulfavirine/VM1500A Long Acting Injectable Formulations (IAS 2017)

Elsulfavirine as Compared to Efavirenz in Combination with TDF/FTC: 48 Week Study (CROI 2017)

PE7/4 Safety and Antiviral Effect of Elpida (VM-1500), a Novel NNRTI (+ Truvada) in Treatment-Naive HIV-1 Infected Patients (EACS 2015)

A Randomized, Placebo-Controlled, Double-Blind Study of VM-1500 in HIV-Naive Patients (CROI 2014)

Pharmacokinetics of VM-1500 20 mg and 40 mg in Healthy and HIV-Infected Patients (AIDS 2014)